Exploration of the biological effects of a basic Phospholipase A, from Agkistrodon piscivorus piscivorus venom



Merideth Harvey¹, Emelyn Salazar¹, Oscar Sanchez¹, Montamas Suntravat^{1,2}, Elda E. Sánchez^{1,2*} ¹ National Natural Toxins Research Center, Texas A&M University- Kingsville, Kingsville, TX, USA ² Department of Chemistry, Texas A&M University- Kingsville, TX, USA Correspondence to: elda.sanchez@tamuk.edu

Background

Phospholipases A₂ (PLA₂s) are found in abundance in the venom of many North American snake species, making up 1.8% to 7%. They are responsible for a wide array of pharmacological effects such as anticoagulation, edema, and inflammatory response^[1,2]. In A. p. piscivorus (A.p.p.) venom, these toxins make up a significant portion of venom constituents (Fig. 1).

A basic PLA₂ was recently isolated through reverse phase HPLC and identified as a D-49 PLA₂ (A.p.p. PLA₂). After testing activities on an in vivo model, the release of proinflammatory mediators, systemic myotoxicity, and hemolytic effects were observed. This study aims to explore the hematological, myotoxic and pro-inflammatory activities of this toxin using in vitro models.

Using Human Umbilical Vein Endothelial Cells (HUVEC) and a myoblast cell line (C2C12) as experimental models, we tested cell viability, cell activation molecule expression, and cell damage markers. These assays are conducted in order to better understand if this PLA₂ is able to trigger an exasperated response in muscle and endothelial cells, thus contributing to the pathophysiology of snake bite envenomation.



Figure 1. Snake venom protein composition for A. p. piscivorus





Analysis

Conclusions

- Significant PLA₂ activity was detected in crude A. p. piscivorus venom and its purified toxin, A.p.p. PLA₂ (Fig. 2).
- *A.p.p.* PLA₂ altered cell viability in C2C12 cells but not HUVEC (Fig. 3).
- At 3 h, the release of IL-8 was detected in all treatments except for TNF- α (Fig. 4A).
- Release of IL-6 was detected, but there were no significant differences compared to the negative control (Fig. 4B).
- There was an increase of pro-inflammatory mediators in cells treated with 6.25 μg/mL of PLA₂ and the positive controls after 24 h incubation, but not with the crude venom or with those treated with 25 μ g/mL of PLA₂ (Fig. 4).
- PLA₂ induced the release of cytokines at 3 and 24 hr (Fig. 4).
- The A.p.p. PLA₂ from the venom of the A. p. piscivorus appears to activate endothelial cells.
- Significant activities were detected in the activated clot time, clot rate and platelet function of human whole blood by crude venom and the PLA_2 (Fig. 5).



was read at 450 nm every minute for five minutes (A). There was a remarkable activity for both the isolated PLA₂ and A.p.p. crude venom at multiple concentrations, being the A.p.p. PLA₂ more potent, activity at lower concentrations compared to the crude venom (B). Blank: PBS, Positive control: Bee venom.



Figure 3. Cell Viability in HUVEC and C2C12. Cells were incubated with A.p.p. PLA₂ (A) and A.p.p. crude venom (B) for 24 h, and cell viability was detected using the MTT assay. Cell viability of C2C12 (orange) was reduced when treated with both the toxin and the crude venom. Meanwhile, HUVEC viability (blue) was only affected by the crude venom. PBS: Negative control. TX-100: Positive control



Figure 4. Detection of pro inflammatory mediators using ELISA. We tested the release of the pro-inflammatory mediators IL-8 (A) and IL-6 (B). Cells were incubated at 3 h (green) and 24 h (red) with the A.p.p. PLA₂ and controls. Supernatants were collected and the release of IL-8 (A) and IL-6 (B) were measured using commercial kits (ThermoFisher Scientific, USA). Negative controls: untreated cells (U/T). Positive controls: A. p. piscivorus crude venom (App CV); Interleukin 1-beta (IL-1 β); Tumor necrosis factor alpha (TNF- α); Lipopolysaccharide (LPS). * p< 0.05 vs. U/T.

Figure 2. PLA, Activity employing Ellmans' reagent (DTNB). PLA, activity was determined using a commercial kit (Cayman Chemicals, USA). The plate







Figure 5. Blood signature profiles generated by SONOCLOT. Significant changes were observed for activated clot time (ACT) (A), clot rate (B) and platelet function (C). These tests were conducted on whole blood samples. *p<0.05 vs. PBS control.

Acknowledgements

Funding for the project was granted by the NIH/ORIP, Viper Resource Grant 5P40OD010960-14 (NNTRC, Texas A&M University-Kingsville, Dr. E.E. Sánchez). We want to thank Nora Diaz De Leon, Mark Hockmuller, Juan Salinas and the rest of the NNTRC personnel for their assistance.

References

- 1. Montecucco, C., et al. (2008). Cell. Mol. Life. Sci., 65.2897-2912
- 2. Calhoun, W., et al. (1989). Agents Actions, 27(3-4), 418-421
- 3. Bruno, L., et al. (1999). Toxicon, 37, 145-158